Personalized briefing
Top 5 discoveries · Oncology
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
Dear Eileen O’Reilly — this week’s five most relevant discoveries, curated for your work in Oncology.
Key findings
Medicine · Thoracic Oncology
No. 1
In previously treated advanced non–small-cell lung cancer with a KRAS G12C mutation, divarasib achieved a median progression-free survival of 9.8 months versus 5.7 months with sotorasib or adagrasib. The comparison establishes a clear progression-free survival advantage for divarasib over existing KRAS G12C inhibitors in this population. For clinical practice, the difference is immediately relevant to treatment selection, sequencing, and trial design in KRAS G12C–mutated NSCLC.
Novelty
88%
Rigor
93%
Significance
95%
Validity
91%
Clarity
94%
Medicine · Genitourinary Oncology
No. 2
Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways
The article introduces key performance metrics to evaluate benefits and harms across prostate cancer diagnostic pathways. It frames the assessment around measurable outcomes that can compare diagnostic strategies rather than relying on single-pathway performance alone. For clinical practice, these metrics provide a structure for weighing diagnostic benefit against harm when designing or comparing prostate cancer pathways.
Novelty
72%
Rigor
78%
Significance
80%
Validity
76%
Clarity
82%
Medicine · Gynecologic Oncology
No. 3
“Low-Risk” Ovarian Lesions—The Case for Early Follow-Up
This Viewpoint argues for earlier follow-up of low-risk but measurable lesions according to the Ovarian-Adnexal Reporting and Data System. It positions follow-up timing as a management question for lesions whose imaging features are measurable yet fall into a low-risk category. For oncology practice, the argument is relevant to surveillance scheduling and to balancing resource use against the risk of missed progression in low-risk lesions.
Novelty
58%
Rigor
55%
Significance
70%
Validity
64%
Clarity
86%
Medicine · Geriatric Oncology
No. 4
No cancer research without older adults, from prevention to end of life: a manifesto
The manifesto calls for systematic inclusion of adults aged 65 and older across cancer research, from prevention through end-of-life care. It argues that funders, regulators, researchers, and journals should make inclusion the norm rather than an exceptional design feature. For a clinical and translational researcher, this is a direct challenge to trial eligibility, endpoint selection, and the generalizability of oncology evidence for the patients who make up most cancer diagnoses.
Novelty
65%
Rigor
50%
Significance
84%
Validity
72%
Clarity
90%
Medicine · Breast Cancer Epidemiology
No. 5
Stat Bite: Breast cancer subtype incidence rates in women under 50 from 2019 to 2023
The report shows that among women under 50, non-Hispanic Asian/Pacific Islander and non-Hispanic White women have the highest rates of HR+/HER2− breast cancer. It also notes that non-Hispanic Black women under 50 have nearly twice the rate of HR−/HER2− disease compared with all other racial and ethnic groups. For oncology research and practice, these subtype-specific disparities are relevant to risk stratification, trial accrual, and the design of prevention and early-detection strategies.
Novelty
48%
Rigor
82%
Significance
74%
Validity
78%
Clarity
88%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
